| Symbol | LEGN |
|---|---|
| Name | LEGEND BIOTECH CORP |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | 2101 COTTONTAIL LANE, SOMERSET, NJ 08873 |
| Telephone | 732-850-5598 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001801198 |
| Description | None |
📋 Casey Patrick John (Director) plans to sell 3K shares of Legend Biotech Corp (at $29.60 each, total $89K) Filed: Jun 30, 2026 | ID: 004966
Read moreHuang Ying 🔴 sold 5.6K shares of Legend Biotech Corp (LEGN) at $14.78 Transaction Date: Jun 25, 2026 | Filing ID: 000006
Read more📋 Huang Ying (Officer) plans to sell 3K shares of Legend Biotech Corp (at $28.39 each, total $79K) Filed: Jun 26, 2026 | ID: 004918
Read moreNew Form 424B5 - Legend Biotech Corp <b>Filed:</b> 2026-06-17 <b>AccNo:</b> 0001193125-26-274318 <b>Size:</b> 972 KB
Read moreNew Form F-6EF - Legend Biotech Corp <b>Filed:</b> 2026-06-17 <b>AccNo:</b> 0001104659-26-075190 <b>Size:</b> 402 KB
Read moreLegend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Read moreLegend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Read moreLegend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
Read more